Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Compounds in development at Shionogi reverse oncogene-induced cell transformation

May 24, 1999

Positive findings from phase I trial of LY-353381 reported at ASCO meeting, lead to phase II study

May 21, 1999

PDT with temoporfin is a promising treatment for GI tumors

May 21, 1999

CCK-B/gastrin antagonist CR-2945 prevents colorectal cancer in mice

May 21, 1999

First proteasome inhibitor in clinical development profiled at oncology meeting

May 20, 1999

Favorable pharmacokinetic, safety and efficacy profile for FMdC in phase I; phase II trials begin

May 20, 1999

Leinamycin derivative selected by Kyowa Hakko for further development

May 20, 1999

Inhibitors of Ras prenylation with bicyclic structure designed at Merck & Co.

May 20, 1999

Endocyte and NCI enter vitamin-targeted anticancer therapy collaboration

May 20, 1999

Novel vaccine increases survival in melanoma patients

May 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.